MWP
SRPT icon

MYCIO Wealth Partners’s Sarepta Therapeutics SRPT Stock Holding History

MYCIO Wealth Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-700
Closed -$13K – 1016
2016
Q2 		$13K Hold
700
– – ﹤0.01% 534
2016
Q1 		$14K Hold
700
– – ﹤0.01% 487
2015
Q4 		$27K Buy
700
+200
+40% +$6.49K ﹤0.01% 377
2015
Q3 		$16K Buy
+500
New +$17K ﹤0.01% 483

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

MYCIO Wealth Partners's SRPT Position: Q3 2016 in Review

MYCIO Wealth Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 700 shares — an estimated $13K sold.

MYCIO Wealth Partners first reported a position in SRPT in Q3 2015 and held it in 4 quarters. The position peaked at $27K in Q4 2015. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • MYCIO Wealth Partners reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
  • MYCIO Wealth Partners sold 700 Sarepta Therapeutics shares in Q3 2016, an estimated $13K.
  • MYCIO Wealth Partners first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 4 quarters.
  • MYCIO Wealth Partners's Sarepta Therapeutics position peaked at $27K in Q4 2015.
  • 186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on MYCIO Wealth Partners's 13F filing for Q3 2016, filed 3 Nov 2016.